Minerva Neurosciences (NASDAQ:NERV) Upgraded to Hold at Wall Street Zen

Minerva Neurosciences (NASDAQ:NERV) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other equities research analysts have also weighed in on NERV. Weiss Ratings reissued a “sell (d-)” rating on shares of Minerva Neurosciences in a research note on Monday, December 29th. HC Wainwright decreased their price target on Minerva Neurosciences from $5.00 to $4.00 and set a “neutral” rating on the stock in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $4.00.

Minerva Neurosciences Stock Performance

NERV stock opened at $6.60 on Friday. The firm has a market cap of $285.58 million, a P/E ratio of -3.57 and a beta of -0.22. The firm’s fifty day moving average is $4.87 and its 200 day moving average is $3.72. Minerva Neurosciences has a 52 week low of $1.15 and a 52 week high of $12.46.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Apella Capital LLC lifted its holdings in Minerva Neurosciences by 7.8% in the 4th quarter. Apella Capital LLC now owns 42,380 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 3,066 shares during the period. State Street Corp raised its holdings in shares of Minerva Neurosciences by 45.4% during the fourth quarter. State Street Corp now owns 24,019 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 7,500 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in Minerva Neurosciences in the fourth quarter worth $36,000. Renaissance Technologies LLC boosted its holdings in Minerva Neurosciences by 28.1% in the fourth quarter. Renaissance Technologies LLC now owns 149,200 shares of the biopharmaceutical company’s stock valued at $600,000 after acquiring an additional 32,700 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in Minerva Neurosciences during the 4th quarter valued at $554,000. Hedge funds and other institutional investors own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.